Ondine Biomedical (LON:OBI) Trading 13.5% Higher – Should You Buy?

Ondine Biomedical Inc. (LON:OBIGet Free Report) traded up 13.5% on Monday . The stock traded as high as C$14.80 and last traded at C$14.75. 1,840,294 shares were traded during trading, an increase of 304% from the average session volume of 455,772 shares. The stock had previously closed at C$13.00.

Ondine Biomedical Trading Up 13.5%

The company has a quick ratio of 8.26, a current ratio of 1.23 and a debt-to-equity ratio of 11.85. The firm has a market capitalization of C$7.66 billion, a PE ratio of -2.11 and a beta of 0.32. The stock’s fifty day simple moving average is C$13.10 and its 200 day simple moving average is C$10.89.

About Ondine Biomedical

(Get Free Report)

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings. We are focused on solutions that address significant needs, are easy to deploy, are environmentally safe, provide substantial public health benefits, and cost a fraction of the infections they target.

Our photodisinfection technology has been used successfully for many years in more than 100,000 patient treatments in hospitals, clinics, and industrial settings across Canada.

Read More

Receive News & Ratings for Ondine Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ondine Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.